50% off Premium Yearly

NYSE:ABT
This summary was created by AI, based on 13 opinions in the last 12 months.
Abbott Labs (ABT) has faced significant challenges over the past year, with a general consensus indicating that its stock has been struggling, down approximately 30%. Analysts have noted that despite the recent acquisition and overall strength in its diagnostics and medical devices segments, growth has not met expectations, leading to lowered guidance and a decline in share prices. The stock trades at a relatively attractive price-to-earnings ratio, which many believe does not fully reflect its growth potential, especially in light of the company's new cancer treatment acquisition. While some experts maintain a bullish stance, citing the company’s diversified product portfolio and strong balance sheet, caution is advised as the stock continues to experience significant volatility in the market. Overall, while Abbott Labs possesses long-term growth potential, particularly in the healthcare sector, it remains under pressure due to recent performance setbacks and ongoing competition.
Fine managers and company. They hold the record in raising dividends by 48 straight years. Super stable. They do diagnostics, nutrition, though spun off a business to Abbvie about 8 years ago. They trade in mid-20sx in PE, and grow by a decent 10%. Problem is this high valuation, so he'd look elsewhere in this space, Abbvie, which he owns.
ABT vs. JNJ Healthcare is in a more defensive space, moving up during the pandemic. Likes both. JNJ has a fairly nice dividend at 2.5%. 18x forward earnings for 8% growth. Performing decently, but underperforming the S&P. ABT is more in medical devices. Marginally underperforming since last March. 22x earnings with a higher growth rate of 14%. Bit more torque with ABT, and they're also in the Covid detection space. If he had to choose, it would be ABT.
The pharmaceutical sector has not gone anywhere for decades. Now they are starting to act like value stocks. Owns other pharma companies like J&J and Senofi. Now is a good time to put pharma stocks to your porfolio.